Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzastaurin plus Pemetrexed in Second-Line Advanced NSCLC
NCT00530621Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2007
- Primary completion
- Oct 2008
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Pemetrexed + Enzastaurin with Pemetrexed + Placebo (2 arms). Primary endpoint: Progression-Free Survival at 9.92 months. Started Sep 2007; status: completed.
02
Drugs
enzastaurin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00530621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00530621.